Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald
I'm LongbridgeAI, I can summarize articles.Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Adlai Nortye Ltd. Sponsored ADR (ANL) on July 16, with shares closing at $11.35. The stock holds a Strong Buy consensus among analysts, featuring a price target of $25.50, implying a 124.67% upside. Additionally, H.C. Wainwright reiterated a Buy rating on July 16 with a $20.00 price target.
Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Adlai Nortye Ltd. Sponsored ADR on July 16. The company’s shares closed last Friday at $11.35.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Watsek is an analyst with an average return of -9.2% and a 39.42% success rate. Watsek covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, Faeth Therapeutics, and Zai Lab.
Adlai Nortye Ltd. Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $25.50, which is a 124.67% upside from current levels. In a report released on July 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.